Showing posts with label biomarkers. Show all posts
Showing posts with label biomarkers. Show all posts

Wednesday, June 5, 2024

Saturday at #ASCO24 - Science, Opening Session and My Social Media Panel Presentation

Over the next few days I will share my experience at #ASCO24 , the science I learned , amazing people I spoke to and of course my presentation on social media. 

Late in the day on Friday,  I finally got to McCormick Place. The traffic from the airport was dreadful but I arrived in time to pick up my badge from the Faculty Lounge. Then I headed to my favorite sushi place - Nui Sushi for dinner.

Rapid Oral Abstract Session Highlights. (I missed some sessions as I had scheduled a time to practice my presentation. )

Ovarian Cancer: AXL expression can be used as a biomarker in OC. Those with high AXL expression had improved PFS and OS when treated with Bateraxcept in combo with taxol.

Ovarian Cancer: Use of suvemcitug, an anti-VEGF drug with chemo,  met PFS goal 5.49 months vs placebo at 2.73 months.

Ovarian , Fallopian, Peritoneal Cancers: Oral cyclophosphamide can be used together- Objective response rate 40%

President's Speech and Invited Speakers

Dr Lynn Schuchter,President of ASCO, inspiring speech.  

Jonathan Carlson, Microsoft Health Futures, spoke on AI use in medicine

Abraham Verghese , Stanford spoke next relating to the meeting theme Art and Science

Clinical Science Symposium Novel combinations across the gyn cancer spectrum

Ovarian Cancer combinations:

Cervical Cancer mTOR inhibitors

Ovarian Cancer - overcoming PARP resistance , HRD status did not impact response

A review of combos:

Endometrial cancers CTK4 inhibitors 

Future Endometrial Cancer work

I finished the day participating in a panel with Dr Gil Morgan and Dr Gil Lopez  on Harnessing the Power of Social Media. What an honor! Below are a few tweets from the audience. Dr Morgan spoke on using social media to improve global oncology and the The OncoAlert Consortium. Dr Lopez spoke on using social media to advance research and professional development. I spoke on social media to educate patients with cancer and clinicians.


Check back to read posts highlighting Sunday's Session and the connections I made at ASCO with researchers, clinicians and other advocates. 

Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , ,

Tuesday, March 19, 2024

2024 SGO Annual Meeting Sunday March 17th Session Review

 

I started the day off attending an ISS ( Industry Sponsored Symposium) which reviewed the use of ADC's ( antibody drug conjugates ) in gynecologic cancers. The session included patient case reviews where the audience and speakers were asked what treatment they would choose for a patient with a specific treatment experience and co-morbidities. It was very interesting to "listen in" on the discussion. 

The next session was a review by the editors of Gynecologic Oncology and Gyn Oncology Reports of their magazines in terms of readership, reviews and future expansion of clinical guidelines. 

The Presidential Invited Speaker was Erin Diehl who presented on  "F" Words at Work. With a bit of improv she talked about failure, #failfluence and the importance of reframing the failure to improve ourselves.


Focused Plenary IV on ctDNA was an interesting group of abstracts all dealing with using circulating DNA for prediction of disease.

 

This study included a new term for me - Fragmentomics -  the investigation of fragmentation patterns of cell-free DNA (cfDNA). 

This was an interesting proof of concept study

 I also attended the Late Breaking Abstract Session.  

This was an interesting study of using Avutometinib plus defactinib ( Kinase inhibitors)  for Low Grade Serous Ovarian Cancer.

This study did not reach the endpoint expected so the study was ended. We may want all the studies to be successful but we can always learn from studies that are not working. 

Focusing on ARID1A in ovarian clear cell and endometriod endometrial cancers. 

This study compared different diagnostic tests for ovarian cancer in post-menopausal women. 

 

I was pleased to see the rarer ovarian cancers being discussed.

Thanks to Dr.Monica Avila (@MAvilaMD) and CrozrX (@CrozrX) for sharing their insights into the studies presented. 

 

Next post will be what I learned on Monday the last day of the meeting.

Dee

Every Day is a Blessing!

 

Posted by at No comments:
Labels: , , , , , , , , ,

Monday, March 28, 2022

SGO 2022 Annual Meeting - Ovarian Cancer Research

Below find some interesting ovarian cancer research studies I heard at the SGO meeting.

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

Long Term Survival of GOG 252 'Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/GOG Study' J. Walker

 

 What's Next After Bevaciumab Resistance? Targeting Metabolic Vulnerabilities in Ovarian Cancer –  D. Glassman GLSi is a novel therapeutic strategy to treat AVA-resistant ovarian cancer

 

Final Overall Survival Results from SOLO3: Phase III Trial Assessing Olaparib Monotherapy Versus Non-Platinum Chemotherapy in Heavily Pretreated Patients with Germline BRCA1 and/or BRCA2-Mutated Platinum-Sensitive Relapsed Ovarian Cancer –  R. Penson




Investigation of PARP Inhibitor Resistance Through the Analysis of Serially Collected Circulating Tumor DNA (ctDNA) in Ovarian Cancer Patients – Speaker: Y. Kim 

 

Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) – Speaker: K. Moore

 

Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and Psychometric Testing Results of a Patient-Centered Knowledge Measure – Speaker: L. Meyer

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis – Speaker: M. Hardesty

 

 

Prospective, Randomized Trial of Streamlined Genetic Education and Testing for Patients with High Grade Epithelial Ovarian, Fallopian and Peritoneal Cancer – Speaker: R. Previs

 Effectiveness of Platinum-Based Chemotherapy after Progression on Poly ADP Ribose Polymerase (PARP) Inhibitor in Epithelial Ovarian Cancer – Speaker: K. Dugan

Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox

A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial – Speaker: J. Liu , This is a Niraparib and Anlotinib ( kinase inhibitor) combo used in Platinum-Resistant OC (ANNIE Study) Promising combo With tolerable toxicity . PPMD1 mutation may be what leads to resistance in niraparib.


 Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer – D. Richardson


Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 – Speaker: I. Winer

 

Late Breaking Abstracts:

 

Scientific Plenary V: Bullseye! Precision Medicine and Hitting the Right Targets

RNAseq Correlative Biomarkers IFIT1B and VSTM5 Predict Progression Free Survival and Clinical Benefit in a Multi-Site Phase I/II Trial of Olaparib and Tremelimumab for gBRCAm Recurrent Ovarian Cancer –  S. Adams

Turning Cold into Hot: Combination of Pembrolizumab with Bevacizumab and Oral Metronomic Cyclophosphamide Increases Immune Cell Migration into the Tumor Microenvironment in Responding Patients with Recurrent Ovarian Cancer – N. Gaulin



The Role of Mesenchymal Stem Cells in the Ovarian Cancer Precarcinoma Microenvironment – Speaker: T. Orellana

Defining the Impact of Chromobox 2 on the Immune Tumor Microenvironment of High Grade Serous Ovarian Carcinoma –  L. Brubaker

 Stay tuned for a post on Cervical Cancer.

Dee

Every Day is a Blessing! 

Posted by at No comments:
Labels: , , , , , , ,

Tuesday, July 9, 2019

#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing

A number of cancer Twitter communities( #gyncsm, #bcsm, #btsm,#lcsm etc) are joining together for a chat on Biomarkers on Thursday, July 11, 2019 I hope some of my followers will join that chat at 8pm ET. pPathologist Dr. Timothy Craig Allen (@TimAllenMDJD) will be moderating the chat.Learn more by reading the post below by Janet Freeeman-Daily.

#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing
Until just a few years ago, chemotherapy was often the only option for some cancer patients. In just a
few short years, molecular therapies and immunotherapies have become commonplace as treatments
for cancer patients. But determining whether a particular cancer patient is a candidate for these new,
often very expensive, molecular and immunotherapies requires molecular biomarker testing. For manycancer patients and their families, the role of molecular biomarker testing in their diagnosis is a
unfamiliar and confusing. How is testing performed? How is the test result analyzed? What is involvedin getting helpful answers from biomarker testing? Does liquid biopsy have a role?
Pathologists are specialized doctors responsible for answering these questions. They identify any cancercells in the biopsied specimen, and guide the patient’s biomarker testing. Unfortunately, pathologists donot typically speak with patients, so patients and families–and even some doctors–often do not have aclear understanding of the role of molecular biomarker testing in the diagnosis and treatment ofcancers. Learning more about the basics of biomarker testing can help patients and families cut throughthe hype about biomarker testing, understand the patient’s specific disease more thoroughly, and learn what biomarker test results mean to the patient’s cancer treatment.

Please join moderator and pathologist Dr. Timothy Craig Allen (@TimAllenMDJD) at 8 PM Eastern Time
on Thursday, July 11, 2019, for a discussion about the basics of biomarker testing, a subject potentially
affecting all cancer patients and doctors. We will cover the following topics:
• T1: What is a biomarker and how is it identified?
• T2: What is biomarker testing and what is it used for?
• T3: What treatment options can be identified through biomarker testing?
• T4: What biomarker tests should be run for which types of cancers? What is a liquid
biopsy and when is useful?
• T5: Can and should patients pursue biomarker testing for treatment options if their
doctor does not offer it?

Please remember to include #cancersm in ALL your tweets so the other chat participants can see them.
If you need a refresher, read the #LCSM primer on participating in a Twitter chat (the hashtag in your
tweets will be #cancersm, not #LCSM). Note that some tweetchat apps (like tchat.io) will not display
tweets longer than 140 characters. Hope you’ll join us!


Dee
Every Day is a Blessing!
Posted by at 1 comment:
Labels: , , , , ,

Tuesday, March 27, 2018

#SGOmtg Twitter Highlights - Research Highlights Sunday March 25, 2018

Sunday was another busy day of information sharing at the SGO Annual Meeting in New Orleans.
Here are the topics that caught my eye while following the #SGOmtg hashtag.

Ovarian Cancer Maintenance Rucaparib - NOVA Study
Ovarian Cancer - Niraparib and Cost effectiveness
Ovarian Cancer - Parp inhibitor and BRCA status



Endometrial Cancer GOG 86 P Predictive biomarkers of endometrial cancer

Endometrial Cancer PORTEC3

Endometrial - GOG 249

Cervical Cancer - chemo /radiation


Thank you to Rick Boulay,MD, Jolyn Taylor, Don S Dizon, Douglas Levine MD,  Shannon Westin and Deanna Teoh, M.D. for tweeting using the #SGOmtg hashtag so those of us following from a distance can learn.


Dee
Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , ,

Friday, January 24, 2014

Biomarkers for Early Detection of Ovarian Cancer - Webinar


I plan on joining this webinar on Monday the 3rd. Thank you to Elda Rainey of Research Advocacy Network for sharing this information. 

You are invited to participate in an
EDRN Educational Webinar
February 3, 2014  at 1 pm EST
Biomarkers for Early Detection of Ovarian Cancer
photo 
Michael J. Birrer, MD, PhD
Principal Investigator, Early Detection Research Network (EDRN)
Director, Gynecologic Oncology Research Program
Massachusetts General Hospital Cancer Center




Registration is not required. To add this meeting to your calendar program (for example Microsoft Outlook), click this link:
https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&ICS=MI&LD=1&RD=2&ST=1&SHA2=AAAAAnW1KR3xn4URJAmA/0EPt2R3cDgZ5DalJ7pa7TJv0ep3&RT=MiMxMQ%3D%3D

-------------------------------------------------------
To join the online meeting on Feb 3rd at 1 pm EST (Now from mobile devices!)
-------------------------------------------------------
1. Go to https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&PW=NYzE3MGFjN2Y0&RT=MiMxMQ%3D%3D
2. If requested, enter your name and email address.
3. If a password is required, enter the meeting password: Advocates$11
4. Click "Join".
Meeting Number: 732 681 403
Meeting Password: Advocates$11
To view in other time zones or languages, please click the link:
https://cbiit.webex.com/cbiit/j.php?ED=277649062&UID=1754492962&PW=NYzE3MGFjN2Y0&ORT=MiMxMQ%3D%3D

-------------------------------------------------------
To join the audio conference only
-------------------------------------------------------
1. Please call one of the following numbers:
Dial In Number: 1-240-276-6338
2. Follow the instructions that you hear on the phone.
Your Cisco Unified MeetingPlace meeting ID: 732 681 403

-------------------------------------------------------
Dee
Every Day is a Blessing!  
Posted by at No comments:
Labels: , , , , ,
Subscribe to: Posts (Atom)